MC
RYTM icon

Matisse Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Matisse Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,130
Closed -$204K – 164
2020
Q2 		$204K Buy
+9,130
New +$178K 0.07% 134

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Matisse Capital's RYTM Position: Q3 2020 in Review

Matisse Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2020, closing a stake of 9,130 shares — an estimated $204K sold.

Matisse Capital first reported a position in RYTM in Q2 2020 and held it in 1 quarter. The position peaked at $204K in Q2 2020. 115 funds tracked by Wall St. Rank hold RYTM as of Q3 2020.

  • Matisse Capital reported no remaining Rhythm Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Matisse Capital sold 9,130 Rhythm Pharmaceuticals shares in Q3 2020, an estimated $204K.
  • Matisse Capital first reported a position in Rhythm Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Matisse Capital's Rhythm Pharmaceuticals position peaked at $204K in Q2 2020.
  • 115 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2020.

Based on Matisse Capital's 13F filing for Q3 2020, filed 4 Nov 2020.